Evidence map›Paper›PMID 25070839›Full record

ReviewExpert opinion on drug delivery2014

Ferritins as nanoplatforms for imaging and drug delivery.

Zipeng Zhen, Wei Tang, Trever Todd, Jin Xie

Abstract readReview
In one paragraph

Review in Expert opinion on drug delivery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Recombinant ferritins for multimodal nanomedicine.Journal of enzyme inhibition and medicinal chemistry · 2023
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Protein-based nanoparticles in cancer vaccine development.Nanomedicine : nanotechnology, biology, and medicine · 2019
    Review
  10. Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular immunotargeting.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Biocompatibility of ferritin-based nanoparticles as targeted MRI contrast agents.Nanomedicine : nanotechnology, biology, and medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zipeng ZhenUniversity of Georgia, Department of Chemistry , Athens, GA 30602 , USA.
Wei Tang
Trever Todd
Jin Xie

Funding

Nanoplatform-based combinational therapy against breast cancer R00CA153772 · NCI · UNIVERSITY OF GEORGIA · PI XIE, JIN · 2011 to 2013
$710k
NCI NIH HHS R00 CA153772NCI NIH HHS R00CA153772
6 · The paper itself

Abstract

introductionDue to unique architecture and surface properties, ferritin has emerged as an important class of biomaterial. Many studies suggest that ferritin and its derivatives hold great potential in a wide range of bio-applications. AREAS COVERED: In this review, we summarize recent progress on employing ferritins as a platform to construct functional nanoparticles for applications in MRI, optical imaging, cell tracking, and drug delivery. EXPERT OPINION: As a natural polymer, ferritins afford advantages such as high biocompatibility, good biodegradability, and a relatively long plasma half-life. These attributes put ferritins ahead of conventional materials in clinical translation for imaging and drug delivery purposes.

Indexed as

AnimalsBiocompatible MaterialsContrast MediaFerritinsHalf-LifeHumansNanocapsulesPhotosensitizing AgentsSurface PropertiesBiocompatible MaterialsContrast MediaFerritinsNanocapsulesPhotosensitizing Agentsdrug deliveryferritinMRInanomedicinereporter gene

Identifiers

PMID25070839
PMCPMC4885637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.